184766-55-0 Usage
Description
4-[2-(5-(2-METHYL-1,3-DIOXOLAN-2-YL)-2-PYRIDYL]ETHOXY]-BENZALDEHYDE is a complex organic compound characterized by its unique molecular structure. It is a yellow oil, which indicates its non-crystalline and liquid nature at room temperature. 4-[2-(5-(2-METHYL-1,3-DIOXOLAN-2-YL)-2-PYRIDYL]ETHOXY]-BENZALDEHYDE serves as an intermediate in the synthesis of metabolites of Pioglitazone, a medication used to treat type 2 diabetes.
Uses
1. Pharmaceutical Industry:
4-[2-(5-(2-METHYL-1,3-DIOXOLAN-2-YL)-2-PYRIDYL]ETHOXY]-BENZALDEHYDE is used as a chemical intermediate for the synthesis of metabolites of Pioglitazone (P471000). Its role in the pharmaceutical industry is crucial for the development and production of medications that help manage type 2 diabetes.
2. Chemical Research and Development:
As a complex organic compound, 4-[2-(5-(2-METHYL-1,3-DIOXOLAN-2-YL)-2-PYRIDYL]ETHOXY]-BENZALDEHYDE may also be used in various chemical research and development applications. Its unique structure and properties can be explored for potential use in the creation of new compounds or materials with specific characteristics and functions.
Check Digit Verification of cas no
The CAS Registry Mumber 184766-55-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,4,7,6 and 6 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 184766-55:
(8*1)+(7*8)+(6*4)+(5*7)+(4*6)+(3*6)+(2*5)+(1*5)=180
180 % 10 = 0
So 184766-55-0 is a valid CAS Registry Number.
InChI:InChI=1/C18H19NO4/c1-18(22-10-11-23-18)15-4-5-16(19-12-15)8-9-21-17-6-2-14(13-20)3-7-17/h2-7,12-13H,8-11H2,1H3
184766-55-0Relevant articles and documents
Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone
Tanis, Steven P.,Parker, Timothy T.,Colca, Jerry R.,Fisher, Roberta M.,Kletzein, Rolf F.
, p. 5053 - 5063 (2007/10/03)
Pioglitazone (5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4- thiazolidinedione, 2) is a prototypical antidiabetic thiazolidinedione that had been evaluated for possible clinical development. Metabolites 6-9 have been identified after dosing of rats and dogs. Ketone 10 has not yet been identified as a metabolite but has been added to the list as a putative metabolite by analogy to alcohol 6 and ketone 7. We have developed improved syntheses of pioglitazone (2) metabolites 6-9 and the putative metabolite ketone 10. These entities have been compared in the KKA(y) mouse model of human type-II diabetes to pioglitazone (2). Ketone 10 has proven to be the most potent of these thiazolidinediones in this in vivo assay. When 6-10 were compared in vitro in the 3T3-L1 cell line to 2, for their ability to augment insulin-stimulated lipogenesis, 10 was again the most potent compound with 6, 7, and 9 roughly equivalent to 2. These data suggest that metabolites 6, 7, and 9 are likely to contribute to the pharmacological activity of pioglitazone (2), as had been previously reported for ciglitazone (1).